Clinical Trial Failure Risk: The success of Savara's lead product candidate, Molgradex for aPAP, heavily depends on positive results from ongoing and future clinical trials. Failure to meet primary or secondary endpoints could lead to significant delays, increased costs, or abandonment of the program, negatively impacting the company's prospects.

Regulatory Approval Uncertainty Risk: Even with positive clinical data, there is no guarantee that regulatory bodies like the FDA or EMA will approve Molgradex for marketing. The approval process is complex and subject to various interpretations and requirements, and any rejection or delay could severely impact the company's ability to generate revenue.

Commercialization and Market Adoption Risk: If Molgradex receives regulatory approval, Savara faces challenges in successfully commercializing and achieving broad market adoption. This includes establishing effective sales and marketing capabilities, securing favorable pricing and reimbursement, and overcoming competition and physician reluctance to prescribe new treatments for a rare disease.